drugset / Trial / NCT07625618
A Pharmacokinetic and Safety Study of MY008211A Tablets in Subjects With Impaired or Normal Hepatic Function
Non-randomizedParallel-groupOpen-labelPrevention
Summary
This study is a single-center, non-randomized, open-label, parallel, single-dose study to evaluate the PK profile and safety of MY008211A Tablets in subjects with hepatic impairment.
Timeline
- Start
- 2024-09-20
- Primary completion
- 2024-12-28
- Completion
- 2024-12-28
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | MY008211A | Unknown | 400 mg | Oral |